This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: A81.9 (atypical virus infection of the central nervous system, unspecified - including prion disease NOS) | Special Copayment Reduction: V282 (severe intractable disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Prion disease NOS, atypical virus infection of the central nervous system, unspecified, spongiform encephalopathy NOS; this code applies when subclassification such as CJD (Creutzfeldt-Jakob disease), vCJD, GSS (Gerstmann-Sträussler-Scheinker syndrome), or FFI (fatal familial insomnia) is not possible |
| C. Adult onset | Likelihood of first onset in adulthood: very high - the mean age of onset of sporadic CJD is in the 60s-70s, and almost all patients develop it in adulthood. GSS and FFI also mainly arise in the 30s-60s. |
| 1. History | 1920-21: Creutzfeldt and Jakob's descriptions → 1936: description of Gerstmann-Sträussler-Scheinker syndrome → 1982: Prusiner establishes the prion concept → 1986: bovine spongiform encephalopathy (BSE) outbreak in the UK → 1996: first report of vCJD → 1997: Prusiner's Nobel Prize → 2009: molecular basis of FFI and GSS fully elucidated. |
| 2. Causes | Abnormal-form prion protein (PrPSc). Sporadic (~85%): spontaneous misfolding of PrPC. Hereditary (~15%): PRNP pathogenic variants. Acquired/transmissible (~1%): exposure to exogenous PrPSc (iatrogenic, cannibalism, BSE beef). |
| 3. Genetics | PRNP gene (20p13): the codon 129 (Met/Val) polymorphism determines the clinical form and prognosis of sCJD. Hereditary forms: D178N (FFI), P102L (GSS), E200K, V210I, M129V, etc. Risk of sCJD and vCJD onset is high in codon 129 homozygotes (MM, VV). |
| 4. General epidemiology | Sporadic CJD: about 1-2 per million per year. About 400-700 per year worldwide. In Korea, about 30-50 CJD cases per year have been reported since the 2000s. Hereditary forms are about 15% of sporadic. vCJD: about 230 cases centered in the UK, now effectively at the end. |
| 5. Pathophysiology | PrPC → PrPSc conversion (template-directed reaction): the abnormal prion converts the normal form in a chain → aggregate formation → neuronal apoptosis → spongiform change, amyloid plaques, gliosis. Cell death mechanisms: ER stress, UPR (unfolded protein response), mitochondrial dysfunction, autophagy impairment. |
| 6. Symptoms | sCJD: rapidly progressive dementia, myoclonus, cerebellar ataxia, visual disturbance, cortical blindness. vCJD: psychiatric symptoms (depression, anxiety) first → neurologic symptoms (sensory abnormalities, ataxia, dementia). GSS: cerebellar ataxia predominant. FFI: progressive insomnia, autonomic abnormalities, movement abnormalities. |
| 7. Signs | sCJD: EEG periodic sharp wave complexes (PSW), CSF 14-3-3 protein positive, CSF RT-QuIC positive (sensitivity ~95%), MRI DWI cortical and basal ganglia ribboning sign. vCJD: MRI pulvinar sign (posterior thalamic T2 hyperintensity). PRNP gene analysis confirms hereditary forms. |
| 8. Screening | No general population screening. PRNP genetic testing and genetic counseling when there is a family history of hereditary prion disease. Screening for vCJD risk classification in blood and transplant donors. Immediate CSF RT-QuIC testing is recommended in patients with rapidly progressive dementia. |
| 9. Diagnosis | WHO diagnostic criteria (2019): definite (brain autopsy/biopsy pathology), probable (clinical + EEG + CSF + MRI), possible (clinical criteria only met). CSF RT-QuIC (sensitivity ~92%, specificity ~99%) is the core of modern diagnosis. PRNP genetic testing. Brain biopsy: when clinically uncertain. |
| 10. Treatment | No curative treatment. Supportive and palliative care. Anti-prion drugs under study: doxycycline (in clinical trials), antisense oligonucleotide (PRN100), small-molecule aggregation inhibitors. Clonazepam and valproic acid for seizures and myoclonus. Symptomatic treatment for pain, anxiety, and sleep disturbance. |
| 11. Prognosis | Fatal in all forms. sCJD: median survival about 4-6 months, 1-year survival 10-15%. vCJD: median survival 14 months. GSS: several years (2-10 years). FFI: 7-36 months. Quality of life can be improved with early diagnosis and supportive treatment. |
| 12. Prevention | vCJD: restrict foods from BSE risk cattle parts (SRM). Iatrogenic CJD: surveillance of high-risk medical procedures such as dura mater grafts and growth hormone injections, special sterilization of prion-contaminated instruments. Hereditary: PRNP genetic counseling and PGT. vCJD risk classification of blood donors. |
| 13. References | Zerr I, Schmitz M, Karch A, et al. Monitoring the prevalence of sCJD. Ann Neurol. 2021 … and 9 other papers |
The history of prion disease is an intellectual journey that begins with the description of independent neurological diseases in the early 20th century and leads to the establishment of a completely new concept of infection, the prion. In 1920-1921, the German neurologists Hans Gerhard Creutzfeldt and Alfons Jakob independently described patients with rapidly progressive dementia and neurologic abnormalities. This disease was later named Creutzfeldt-Jakob disease (CJD) after them.
In 1936, the Austrians Josef Gerstmann, Ernst Sträussler, and Ilya Scheinker reported a familial neurological disease with cerebellar ataxia as the main symptom, which was later established as Gerstmann-Sträussler-Scheinker syndrome (GSS). In 1986, Fatal Familial Insomnia (FFI) was first described in Italy.
In 1986, bovine spongiform encephalopathy (BSE, also called "mad cow disease") was first reported in the UK, and in 1996 Robert Will et al. in the UK described a new form of CJD (variant CJD, vCJD), raising a link to BSE. vCJD was distinguished by onset at a young age, a clinical course in which psychiatric symptoms come first unlike sCJD, and a characteristic pulvinar sign on MRI. About 230 vCJD patients have been identified, centered on the UK and France.
The theoretical unification of prion diseases came in 1982 with Stanley Prusiner's proposal of the prion concept. Prusiner argued that transmission of scrapie, CJD, and kuru is mediated by an abnormal protein (PrPSc) that contains no nucleic acid, and he received the 1997 Nobel Prize in Physiology or Medicine for a series of experiments proving this. Prion disease is now a core model for research on neurodegenerative diseases, and a similar "misfolded protein propagation" mechanism is being studied in Alzheimer disease, Parkinson disease, ALS, and others.
The common cause of all prion diseases is that normal prion protein (PrPC) is converted to an abnormal tertiary structure (PrPSc), forming aggregates and exerting neurotoxicity. According to the mechanism of occurrence, they are classified into three forms.
Sporadic CJD (sCJD, ~85%): Understood to arise without exposure to exogenous PrPSc or a pathogenic PRNP gene variant, through spontaneous misfolding of PrPC. The exact spontaneous conversion mechanism has not been fully elucidated and is explained as a stochastic molecular event. The increase in incidence with aging suggests that the possibility of this spontaneous conversion is time-dependent.
Hereditary prion disease (~15%): Pathogenic variants of the PRNP gene promote PrPSc conversion or destabilize the normal PrP structure. Major variants and associated diseases: E200K (the most common hereditary CJD, high frequency in the Libyan Jewish population), D178N+M129 (FFI), D178N+V129 (hereditary CJD), P102L (GSS), octapeptide repeat insertion variants (gCJD), V210I, M232R, etc. Inherited in an autosomal dominant manner, and a family history is important for diagnosis.
Acquired/transmissible prion disease (~1%): Occurs through exposure to exogenous PrPSc. Iatrogenic CJD (iCJD): transmitted through dura mater grafts (Lyodura products), injections of cadaver-derived growth hormone, use of contaminated brain electrodes, etc. Variant CJD (vCJD): transmitted by eating food containing specified risk materials (SRM) from BSE-infected cattle. Kuru: transmitted by the cannibalistic customs of the Fore tribe (now eradicated).
The role of genetics in prion disease is of two main kinds: ① pathogenic PRNP variants that directly cause hereditary prion disease, and ② polymorphisms that modulate susceptibility, clinical form, and prognosis of sporadic and acquired prion disease.
The PRNP gene is located on the short arm of chromosome 20 (20p13) and encodes the 253-amino acid prion protein (PrP) in a single exon. PrP is a glycoprotein attached to the neuronal surface mainly by a GPI anchor, and is known to have various physiological functions such as copper binding and cell signaling, but these have not been fully elucidated.
The codon 129 (Met/Val) polymorphism is the most important locus in prion disease genetics. The genotype at this position (MM, MV, VV) is directly linked to the clinical form of sCJD: it is subdivided into MM1 type (about 70% of sCJD, rapid progression, characteristic EEG PSW), MM2 type, MV1, MV2 types, VV1, VV2 types, and so on. In almost all confirmed vCJD patients, the codon 129 genotype was homozygous MM, and some MV patients have recently been reported. Codon 129 heterozygotes (MV) have relative resistance to prion diseases, including sporadic CJD.
More than 40 pathogenic variants of hereditary prion disease are known. Representative ones: PRNP D178N (FFI when combined with codon 129 Met, hereditary CJD when combined with Val), P102L (the most common GSS variant), A117V (GSS), E200K (hereditary sCJD-like, with a significant founder effect), Y163X (a new GSS type), and octapeptide repeat insertion (gCJD/GSS). Hereditary prion disease is autosomal dominant with nearly complete penetrance. When there is a family history, PRNP genetic testing and genetic counseling are essential.
Prion disease is a rare neurodegenerative disease worldwide, with sporadic CJD (sCJD) accounting for about 85% of the total. The worldwide incidence of sCJD is consistently reported at about 1-2 per million per year. Age of onset is mostly in the 60s-70s, and onset under age 50 is rare. There is no difference in incidence between men and women. Annual sCJD occurrence worldwide is estimated at about 400-700, and may be higher considering cases not actually diagnosed.
Hereditary prion disease is about 15% of sporadic, and clustering due to a founder effect is observed in specific regions. The E200K variant occurs at high frequency in the Libyan Jewish population (about 100 per million), the Slovak Roma population, and some regions of Chile. In Korea there are no reports of cluster occurrence of specific variants related to hereditary CJD, but surveillance of prion disease, including sporadic CJD, is carried out.
Epidemiology in Korea: In Korea, prion diseases including CJD have been included in the national surveillance system (Korea Disease Control and Prevention Agency infectious disease surveillance) and reported since the 2000s. About 30-50 CJD cases are notified per year, of which sporadic CJD accounts for most. There are no officially confirmed vCJD cases in Korea. In 2008, concern about vCJD (mad cow disease) over the resumption of US beef imports became socially prominent in Korea, but the epidemiologic risk was subsequently assessed scientifically as low. Matters of special interest in Korea include safety management of dura mater grafts and growth hormone to prevent iatrogenic CJD.
Worldwide, about 230 cases of vCJD have been identified, including the UK (about 178), France (27), and other countries, and new occurrence has effectively disappeared since the mid-2000s. A UK tonsil screening study raised the possibility that about 1 in 2,000 of the population may be in a state of asymptomatic vCJD prion infection with codon 129 MM type, but there is no definitive conclusion.
The core pathophysiology of prion disease is the chain reaction of PrPC → PrPSc conversion and the resulting neuronal death. Normal PrPC is a protein rich in alpha-helical structure (~40% α-helix, ~3% β-sheet), whereas PrPSc is a misfolded form rich in beta-sheet structure (~43% β-sheet, ~30% α-helix). This structural conversion is not reversible, and it is amplified autocatalytically through "template-directed refolding" or "nucleation-polymerization" reactions in which PrPSc uses normal PrPC as a template and converts it to the abnormal form.
PrPSc aggregates form a hierarchical structure of monomer → oligomer → fibril → amyloid plaque through intermolecular binding. The actual mediator of neuronal toxicity is increasingly recognized to be the soluble oligomer of PrPSc, and there are studies showing that oligomers have higher cytotoxicity than large insoluble aggregates.
Several pathways have been proposed for the cell death mechanism: ① endoplasmic reticulum (ER) stress and UPR (unfolded protein response) - abnormal PrP accumulates in the ER and overactivates the UPR, and through translational inhibition (overactive eIF2α phosphorylation) globally blocks protein synthesis and induces neuronal death; ② impaired autophagy; ③ synaptic dysfunction - PrPSc oligomers interfere with synaptic transmission, collapsing the functional network; ④ mitochondrial dysfunction - oxidative stress and decreased ATP production.
Spongiform change, the macroscopic pathologic finding of the disease, appears as intracytoplasmic vacuole formation and is characterized by a sponge-like change of brain tissue. Neuronal loss, reactive astrogliosis, microglial activation, and amyloid plaque formation accompany it.
The clinical symptoms of prion disease vary by form, but are in common characterized by progressive decline of nervous system function and a fatal course.
Sporadic CJD (sCJD): The most common clinical feature is rapidly progressive dementia, in which cognitive function declines abruptly over weeks to months. This speed is much faster than in other neurodegenerative diseases such as Alzheimer disease and Lewy body dementia. In addition, myoclonus appears in about 80-90% and is often triggered by startling stimuli. Cerebellar ataxia, visual abnormalities (including cortical blindness), pyramidal and extrapyramidal symptoms, and autonomic abnormalities also occur. In the Heidenhain variant (visual variant), visual abnormalities are prominent early.
Variant CJD (vCJD): Occurs mainly in young adults (mean age of onset about 28 years), with psychiatric symptoms (depression, anxiety, social withdrawal, hallucinations) preceding for several months, followed by neurological symptoms (sensory abnormalities, cerebellar ataxia, movement abnormalities, dementia). Dementia tends to appear relatively late in vCJD.
GSS (Gerstmann-Sträussler-Scheinker syndrome): Cerebellar ataxia is the main initial symptom, with slow progression over several years. Dementia appears in the late stage. Age of onset is in the 40s-60s, and the duration of progression is much longer than in CJD (several years to 10 years).
FFI (fatal familial insomnia): Starts with progressively worsening insomnia, reaching a state of complete inability to sleep. Sympathetic overactivity symptoms such as sweating, fever, tachycardia, and hypertension accompany. Afterward it progresses to dementia, movement disorder, and confusional state. Age of onset 40s-60s.
EEG findings: In sCJD, periodic sharp wave complexes (PSWC) appear as the disease progresses. They are triphasic or biphasic complexes repeating at 1-2 second intervals, with a sensitivity of about 67% and a specificity of about 74% for sCJD. The EEG is normal or shows nonspecific abnormalities early in the disease, and PSWC appear after progression.
CSF testing: 14-3-3 protein is positive with about 90-95% sensitivity in sCJD, but specificity is limited (it can also be positive in herpes simplex encephalitis, metabolic encephalopathy, and other rapidly progressive dementias). The most important CSF test at present is RT-QuIC (real-time quaking-induced conversion), which amplifies and detects very small amounts of PrPSc by exploiting the nucleation properties of PrPSc. Since 2019, RT-QuIC positivity has been included in the updated WHO diagnostic criteria, with a sensitivity of about 92% and a specificity of about 99%.
MRI findings: On diffusion-weighted imaging (DWI), cortical ribboning and diffusion restriction in the basal ganglia (especially caudate nucleus and putamen) and thalamus are characteristic imaging findings of sCJD. In vCJD, symmetric T2/FLAIR hyperintensity of the posterior thalamus (pulvinar) and dorsomedial nucleus (pulvinar sign) is characteristic.
Brain autopsy/biopsy pathology: The three elements of spongiform change, neuronal loss, and reactive astrogliosis + PrPSc positivity on immunohistochemistry are the confirmatory criteria. Plaque formation is rare in CJD, but plaques are prominent in vCJD and GSS. In vCJD, "florid plaques" (a halo of spongiform change around a central amyloid core) are characteristic.
Screening for prion disease in the general population is not currently performed because it is not justified cost-effectively. Targeted screening in specific high-risk groups and clinical situations is key.
Screening of those with a family history of hereditary prion disease: When a PRNP pathogenic variant (E200K, D178N, P102L, etc.) has been identified in a family, PRNP genetic testing and genetic counseling are offered to adult family members. A positive result implies overwhelming penetrance for prion disease, so counseling on whether and when to disclose the result is needed.
Screening of blood and transplant donors: Blood donors with a history of high-risk exposure to vCJD (residence in the UK in 1980-1996, consumption of BSE-risk beef) may be restricted from donating according to the guidelines of the transfusion institution. Donation is restricted for organ and tissue donors with a CJD-related family history, dementia of unknown cause, or a history of exposure to iatrogenic CJD risk.
Clinical screening: Patients with rapidly progressive dementia (RPD) must be differentiated for CJD, and immediate CSF RT-QuIC and brain MRI (DWI) are recommended. Causes of RPD include, besides prion disease, autoimmune encephalitis (NMDA receptor encephalitis, etc.), infectious encephalitis, vascular disease, and paraneoplastic syndromes, so comprehensive differential diagnostic testing is performed at the same time.
Prion disease is diagnosed according to the WHO CJD diagnostic criteria revised in 2019, using a three-level diagnostic classification of definite, probable, and possible.
Definite: characteristic neuropathologic findings in brain tissue (biopsy or autopsy) + positive PrPSc immunohistochemistry or Western blot, or positive RT-QuIC.
Probable: ① Neurological criteria (rapidly progressive dementia + 2 or more of the following: myoclonus, visual/cerebellar abnormality, pyramidal/extrapyramidal abnormality, akinetic mutism) + EEG PSWC or positive CSF 14-3-3 or positive CSF/brain tissue RT-QuIC or specific MRI DWI/FLAIR findings. ② Probable vCJD: progressive neuropsychiatric symptoms + MRI pulvinar sign (thalamic sign), etc.
Differential diagnosis: The differential list for rapidly progressive dementia is broad, and autoimmune encephalitis (anti-NMDAR, LGI1, CASPR2, AMPAR, etc.), Hashimoto encephalopathy, infectious encephalitis (herpes simplex virus, etc.), paraneoplastic encephalopathy, vascular causes, and metabolic causes (vitamin B12 deficiency, thyroid disease) must be excluded. Autoimmune encephalitis is clinically similar to CJD but treatable, so early differentiation is very important. A CSF antibody panel (antibodies related to autoimmune encephalitis), endocrine tests, and infection screening should be performed at the same time.
PRNP gene testing: Performed in all patients with suspected prion disease to distinguish familial forms and for molecular classification of sporadic CJD (confirming the codon 129 polymorphism).
There is currently no established curative treatment for prion disease. However, various approaches are being studied at the clinical and preclinical stages.
Supportive and palliative care: This is the whole of current standard treatment. Clonazepam and valproate are used for myoclonus, and seizures are controlled with anticonvulsants. Pain management, treatment of insomnia (in FFI), aspiration prevention, pressure ulcer care, nutritional support (gastrostomy, etc.), and advance care planning are the core. Early collaboration with a palliative care team is recommended.
Drug research: Doxycycline was shown in animal models to inhibit PrPSc aggregation, and clinical trials including hereditary CJD were conducted, but it did not show a significant survival-prolonging effect. PRN100 is a brain-penetrating humanized anti-PrP monoclonal antibody, and experience of its use in a small clinical trial in patients with iatrogenic CJD has been reported. Suppression of PRNP gene expression using antisense oligonucleotides (ASO) has shown a survival-prolonging effect in animal models and clinical development is under way. Small-molecule aggregation inhibitors and CRISPR-based gene editing are at the research stage.
Adjunctive symptomatic therapy: There is no evidence for the use of cholinesterase inhibitors for cognitive decline, but they are tried in some clinical settings. Anxiolytics, antipsychotics, and antidepressants are used to control behavioral symptoms. All treatment is for palliative purposes, focusing on improving quality of life for patients and families.
Prion disease of every form is 100% fatal with current treatment. The mean survival by form is as follows.
Sporadic CJD: Median survival after onset is about 4-6 months, and 1-year survival is about 10-15%. Some patients survive for several years, but this is very rare. Age at onset, clinical molecular type (codon 129 genotype), and initial symptom pattern affect prognosis. The lower the age of onset, and in the cerebellar ataxic type (MV2), progression tends to be somewhat slower.
Variant CJD: Median survival is about 13-14 months, longer than sCJD. The initial period of psychiatric symptoms (several months) is included, so the total duration of illness appears longer than in sCJD.
GSS: The prion disease with the longest course, with a mean survival of 2–10 years (range). It begins with cerebellar ataxia and progresses slowly over several years.
FFI: Death occurs within 7–36 months after symptom onset; progression is relatively rapid.
In all patients, appropriate palliative care and family support are important for quality of life. Because CJD-related deaths pose no risk of prion transmission (it is not transmitted by ordinary contact, air, or food), home care is possible. Brain tissue autopsy is important for public health, so postmortem brain donation is encouraged when consent is obtained.
Prevention of prion disease is differentiated by type.
vCJD prevention: To prevent vCJD from BSE-infected beef, measures have been implemented worldwide, including ① removal of specified risk materials (SRM: brain, spinal cord, eyes, tonsils, and part of the intestine from duodenum to rectum of cattle older than 30 months) from human food and animal feed, ② slaughter and incineration of BSE-affected cattle, and ③ a ban on the use of animal protein (meat and bone meal, MBM) in cattle feed. As a result, BSE cases worldwide have dropped sharply and new vCJD cases have nearly disappeared. In Korea as well, SRM removal standards and an inspection system for imported beef are maintained.
Prevention of iatrogenic CJD (iCJD): ① Dura mater transplantation: use of synthetic dura mater or autologous tissue; no use of dura mater from high-risk CJD donors; ② Growth hormone: use of recombinant growth hormone (cadaver-derived growth hormone prohibited); ③ Handling of prion-contaminated instruments: for PrPSc, which is resistant to ordinary disinfection, a protocol of 2N NaOH treatment for 60 minutes or autoclaving at 134°C (18 minutes) is applied to surgical instruments at risk of prion contamination; ④ Caution regarding prion exposure in neurosurgery — adhere to the instrument-handling protocol when operating on patients with suspected CJD.
Prevention of hereditary prion disease: In families carrying a pathogenic PRNP variant, birth of an affected child can be prevented by offering preimplantation genetic testing (PGT) or prenatal diagnosis through genetic counseling. The ethical principles of presymptomatic genetic testing for adult-onset genetic diseases must be observed.
Zerr I, Schmitz M, Karch A, et al. Subtypes of sporadic Creutzfeldt-Jakob disease and their surveillance. Ann Neurol. 2021;89(3):504-515. DOI: 10.1002/ana.25987. PMID: 33296515.
Geschwind MD. Prion diseases. Continuum (Minneap Minn). 2015;21(6 Neuroinfectious Disease):1612-1638. DOI: 10.1212/CON.0000000000000251. PMID: 26633779.
Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216(4542):136-144. DOI: 10.1126/science.6801762. PMID: 6801762.
Foutz A, Appleby BS, Hamlin C, et al. Diagnostic and prognostic value of human prion detection in cerebrospinal fluid. Ann Neurol. 2017;81(1):79-92. DOI: 10.1002/ana.24833. PMID: 27893164.
Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996;347(9006):921-925. DOI: 10.1016/s0140-6736(96)91412-9. PMID: 8598754.
Llorens F, Schmitz M, Ferrer I, Zerr I. CSF biomarkers in human prion diseases: diagnostic and prognostic role. Prog Neurobiol. 2016;145-146:29-44. DOI: 10.1016/j.pneurobio.2016.08.002. PMID: 27524284.
Caughey B, Kraus A. Transmissibility versus pathogenicity of self-propagating protein aggregates. Viruses. 2019;11(11):1044. DOI: 10.3390/v11111044. PMID: 31717456.
Minikel EV, Vallabh SM, Ike C, et al. PRNP codon 129 genotype prevalence and the penetrance of Creutzfeldt-Jakob disease. Science. 2016;352(6290):1354-1358. DOI: 10.1126/science.aaf7462. PMID: 27284200.
Mead S, Stumpf MP, Whitfield J, et al. Balancing selection at the prion protein gene consistent with prehistoric kurulike epidemics. Science. 2003;300(5619):640-643. DOI: 10.1126/science.1083320. PMID: 12690204.
Kim JK, Nam H, Joo BE, et al. Clinical characteristics and diagnosis of sporadic Creutzfeldt-Jakob disease in Korea. J Clin Neurol. 2016;12(1):63-68. DOI: 10.3988/jcn.2016.12.1.63. PMID: 26526766.